Exemestane FDA approval date

The FDA approved Exemestane on 21 Oct 1999.

FDA approval date
21 Oct 1999

Drug identity checked against registry records

Also recorded as Mestane

Included trials

TrialSponsorPhaseStatusPrimary completion
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast CancerNCT04869943VERUPhase 3Terminated2024-01-09Actual
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738OLMAPhase 3Active not recruiting2026-10-31Estimated

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
1999-10-21DayExemestaneFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA020753", "applicant_as_listed_by_fda": "PFIZER", "brand_names": ["AROMASIN"], "active_ingredients": ["EXEMESTANE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19991021", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026